These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24262157)

  • 1. Behavioral disorders in Parkinson's disease: the role of dopamine.
    Antonelli F; Strafella AP
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S10-2. PubMed ID: 24262157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.
    Chaudhuri KR; Schapira AH
    Lancet Neurol; 2009 May; 8(5):464-74. PubMed ID: 19375664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-motor extranigral signs and symptoms in Parkinson's disease.
    Wolters ECh
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S6-12. PubMed ID: 20083010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-motor disorders in Parkinson's disease].
    Merello M
    Rev Neurol; 2008 Sep 1-15; 47(5):261-70. PubMed ID: 18780273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic dysregulation syndrome in Parkinson's disease.
    Katzenschlager R
    J Neurol Sci; 2011 Nov; 310(1-2):271-5. PubMed ID: 21868039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New pharmacological options for treating advanced Parkinson's disease.
    Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
    Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease.
    Merims D; Giladi N
    Parkinsonism Relat Disord; 2008; 14(4):273-80. PubMed ID: 17988927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nonmotor symptoms of Parkinson's disease--an overview.
    Lim SY; Lang AE
    Mov Disord; 2010; 25 Suppl 1():S123-30. PubMed ID: 20187234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonmotor symptom complex of Parkinson's disease--an under-recognized entity.
    Mehndiratta M; Garg RK; Pandey S
    J Assoc Physicians India; 2011 May; 59():302-8, 313. PubMed ID: 21751608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
    Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
    Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of Parkinson's disease behavior--a view from the network.
    Caviness JN
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S39-43. PubMed ID: 24262185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Parkinson's disease: psychological and behavioral disorders].
    Delgadillo-Iniguez D; Corvol JC; Gély-Nargeot MC; Lacomblez L
    Psychol Neuropsychiatr Vieil; 2006 Dec; 4 Spec No 1():S11-6. PubMed ID: 23631043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Apathy in Parkinson's disease: clinical features, mechanisms and assessment].
    Dujardin K; Defebvre L
    Rev Neurol (Paris); 2012; 168(8-9):598-604. PubMed ID: 22926025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotransmission in Parkinson's disease: beyond dopamine.
    Barone P
    Eur J Neurol; 2010 Mar; 17(3):364-76. PubMed ID: 20050885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact and management of nonmotor symptoms of Parkinson's disease.
    Lyons KE; Pahwa R
    Am J Manag Care; 2011 Oct; 17 Suppl 12():S308-14. PubMed ID: 22087551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
    Bayard S; Cochen De Cock V; Dauvillers Y
    Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment].
    Thobois S; Ardouin C; Schmitt E; Lhommée E; Klinger H; Xie J; Lagrange C; Kistner A; Aya Kombo M; Fleury V; Poisson A; Fraix V; Broussolle E; Pollak P; Krack P
    Rev Neurol (Paris); 2010 Oct; 166(10):816-21. PubMed ID: 20739041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
    Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
    Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of behavioral disorders in Parkinson's disease.
    Valldeoriola F; Molinuevo J
    Biomed Pharmacother; 1999 Apr; 53(3):149-53. PubMed ID: 10349504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.